menu
    • menu
    [{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"WM-S1-030","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Wellmarker Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wellmarker Bio \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"Wellmarker Bio \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"WM-A1-3389","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Wellmarker Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Wellmarker Bio \/ Merck Group","highestDevelopmentStatusID":"4","companyTruncated":"Wellmarker Bio \/ Merck Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Wellmarker Bio

    Menu

    Wellmarker Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Wellmarker Bio

                            South Korea arrow
                            DCAT Week
                            Not Confirmed

                            Wellmarker Bio

                            South Korea arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WM-A1-3389,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Wellmarker Bio Announces Clinical Trial Collaboration With MSD To Evaluate WM-A1-3389 In Combination With KEYT...

                            Details : Under the agreement, WMBIO will sponsor the Phase 1 (or Phase 1b) clinical trial for WM-A1-3389, a novel therapeutic antibody for Non-Small Cell Lung Cancer (NSCLC) patients with low or no PD-L1 expression, in combination with KEYTRUDA (pembrolizumab), M...

                            Product Name : WM-A1-3389

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 07, 2023

                            Lead Product(s) : WM-A1-3389,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Wellmarker Bio

                            South Korea arrow
                            DCAT Week
                            Not Confirmed

                            Wellmarker Bio

                            South Korea arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WM-S1-030

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Labcorp Drug Development

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            WellmarkerBio Receives Approval for Phase I Clinical Trial from the Australian Therapeutic Goods Administratio...

                            Details : Wellmarker has received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive cancer.

                            Product Name : WM-S1-030

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 03, 2021

                            Lead Product(s) : WM-S1-030

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Labcorp Drug Development

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth